Polypeptide Group Ag Stock Return On Asset
| PPGN Stock | CHF 28.95 0.45 1.58% |
PolyPeptide Group AG fundamentals help investors to digest information that contributes to PolyPeptide Group's financial success or failures. It also enables traders to predict the movement of PolyPeptide Stock. The fundamental analysis module provides a way to measure PolyPeptide Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PolyPeptide Group stock.
PolyPeptide |
PolyPeptide Group AG Company Return On Asset Analysis
PolyPeptide Group's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current PolyPeptide Group Return On Asset | 0.0467 |
Most of PolyPeptide Group's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PolyPeptide Group AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, PolyPeptide Group AG has a Return On Asset of 0.0467. This is 100.53% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all Switzerland stocks is 133.36% lower than that of the firm.
PolyPeptide Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PolyPeptide Group's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PolyPeptide Group could also be used in its relative valuation, which is a method of valuing PolyPeptide Group by comparing valuation metrics of similar companies.PolyPeptide Group is currently under evaluation in return on asset category among its peers.
PolyPeptide Fundamentals
| Return On Equity | 0.0809 | |||
| Return On Asset | 0.0467 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 755.81 M | |||
| Shares Outstanding | 33.12 M | |||
| Shares Owned By Insiders | 59.60 % | |||
| Shares Owned By Institutions | 29.93 % | |||
| Price To Book | 1.90 X | |||
| Price To Sales | 2.82 X | |||
| Revenue | 282.13 M | |||
| Gross Profit | 100.91 M | |||
| EBITDA | 83.35 M | |||
| Net Income | 47.26 M | |||
| Cash And Equivalents | 136.3 M | |||
| Cash Per Share | 5.67 X | |||
| Total Debt | 14.95 M | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 2.94 X | |||
| Book Value Per Share | 12.97 X | |||
| Cash Flow From Operations | 57.35 M | |||
| Earnings Per Share | 0.94 X | |||
| Target Price | 28.68 | |||
| Number Of Employees | 1.16 K | |||
| Market Capitalization | 823.49 M | |||
| Total Asset | 595.04 M | |||
| Z Score | 33.0 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 595.04 M | |||
| Last Dividend Paid | 0.29 |
About PolyPeptide Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PolyPeptide Group AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PolyPeptide Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PolyPeptide Group AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for PolyPeptide Stock Analysis
When running PolyPeptide Group's price analysis, check to measure PolyPeptide Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PolyPeptide Group is operating at the current time. Most of PolyPeptide Group's value examination focuses on studying past and present price action to predict the probability of PolyPeptide Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PolyPeptide Group's price. Additionally, you may evaluate how the addition of PolyPeptide Group to your portfolios can decrease your overall portfolio volatility.